Cervical cancer prevented by screening: Long-term incidence trends by morphology in Norway

International Journal of Cancer

Volumn 137, Issue 7, 2015, Pages 1758-1764

  Lönnberg, Stefan ^a   Hansen, Bo Terning ^a   Haldorsen, Tor ^a   Campbell, Suzanne ^a   Schee, Kristina ^a   Nygärd, Mari ^a  

^a CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

cervical cancer; incidence trends; mass screening

Indexed keywords

ADENOSQUAMOUS CARCINOMA; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; CELL STRUCTURE; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MELANOMA; NORWAY; PRIORITY JOURNAL; SECONDARY PREVENTION; TREND STUDY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; WART VIRUS; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; INCIDENCE; MASS SCREENING; MIDDLE AGED; PATHOLOGY; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; NORWAY; UTERINE CERVICAL NEOPLASMS;

EID: 84943415080     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29541     Document Type: Article

References (40)

1. Engholm G, Ferlay J, Christensen N, et al., NORDCAN: cancer incidence, mortality, prevalence and Survival in the Nordic Countries, Version 6.0. Association of the Nordic Cancer Registries. Danish Cancer Society, 2013.
2. Dahlstrom LA, Ylitalo N, Sundstrom K, et al., Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 2010; 127: 1923-30.
3. Mitchell H, Medley G, Gordon I, et al., Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. Br J Cancer 1995; 71: 894-7.
4. Andrae B, Kemetli L, Sparen P, et al., Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008; 100: 622-9.
5. Lonnberg S, Anttila A, Luostarinen T, et al., Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev 2012; 21: 1354-61.
6. Kurman RJ, Carcangiu ML, Herrington CS, et al, eds. WHO Classification of Tumours of Female Reproductive Organs, 4th edn. Lyon: IARC, 2014. 307 p.
7. Sasieni P, Castanon A, Cuzick J,. Screening and adenocarcinoma of the cervix. Int J Cancer 2009; 125: 525-9.
8. Magnus K, Langmark F, Andersen A,. Mass screening for cervical cancer in Ostfold county of Norway 1959-77. Int J Cancer 1987; 39: 311-6.
9. Anttila A, Ronco G, Clifford G, et al., Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004; 91: 935-41.
10. Forsmo S, Buhaug H, Stalsberg H,. Use of pap-smears in a population without a mass screening program. Acta Obstet Gynecol Scand 1994; 73: 824-8.
11. Bjorge T, Gunbjorud AB, Langmark F, et al., Cervical mass screening in Norway-510,000 smears a year. Cancer Detect Prev 1994; 18: 463-70.
12. Bjorge T, Gunbjorud AB, Haugen OA, et al., Mass screening for cervical cancer in Norway: evaluation of the pilot project. Cancer Causes Control 1995; 6: 477-84.
13. Nygard JF, Skare GB, Thoresen SO,. The cervical cancer screening programme in Norway, 1992-2000: changes in pap smear coverage and incidence of cervical cancer. J Med Screen 2002; 9: 86-91.
14. Bilet EF, Langseth H, Thoresen SO, et al., Completeness of invasive cervical cancer at the cancer registry of Norway. Acta Oncol 2009; 48: 1070-3.
15. Fritz A, Percy C, Jack A, et al, eds. International Classification of Diseases for Oncology, 3rd edn. Geneva: World Health Organization, 2000. 240 p.
16. Doll R, Cook P,. Summarizing indices for comparison of cancer incidence data. Int J Cancer 1967; 2: 269-79.
17. Kim HJ, Fay MP, Feuer EJ, et al., Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19: 335-51.
18. Statistical Methodology and Applications Branch SRP, National Cancer Institute: Joinpoint Regression Program, Version 4.04 edn, 2013.
19. Clegg LX, Hankey BF, Tiwari R, et al., Estimating average annual per cent change in trend analysis. Stat Med 2009; 28: 3670-82.
20. Crocetti E, Battisti L, Betta A, et al., The cytological screening turned out effective also for adenocarcinoma: a population-based case-control study in trento, Italy. Eur J Cancer Prev 2007; 16: 564-7.
21. Zappa M, Visioli CB, Ciatto S, et al., Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer 2004; 90: 1784-6.
22. Walboomers JM, Jacobs MV, Manos MM, et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Path 1999; 189: 12-9.
23. International Agency for Research on Cancer. Cervical cancer and screening. In: IARC Handbooks of Cancer Prevention, Vol 10 Cervix Cancer Screening, chapter 1. Lyon: IARC Press, 2005. 1-57.
24. Li N, Franceschi S, Howell-Jones R, et al., Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-35.
25. Giorgi Rossi P, Sideri M, Carozzi FM, et al., Group HPVPIW. HPV type distribution in invasive cervical cancers in Italy: pooled analysis of three large studies. Infect Agent Cancer 2012; 7: 26
26. Castellsague X, Diaz M, de Sanjose S, et al., Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98: 303-15.
27. Pimenta JM, Galindo C, Jenkins D, et al., Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer 2013; 13: 553
28. Tjalma WA, Fiander A, Reich O, et al., Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer 2013; 132: 854-67.
29. de Sanjose S, Quint WG, Alemany L, et al., Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
30. Ronco G, Dillner J, Elfstrom KM, et al., Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524-32.
31. Lehtinen M, Paavonen J, Wheeler CM, et al., Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99.
32. Ault KA;, Future II Study Group. Effect of prophylactic human papillomavirus l1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-8.
33. International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer 2007; 120: 885-91.
34. Smith JS, Herrero R, Bosetti C, et al., International agency for research on cancer multicentric cervical cancer study G. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 1604-13.
35. Medical Birth Registry of Norway [Internet]. Norwegian Institute of Public Health. Available from: http://www.fhi.no/artikler/?id=94819. Published Jan 04, 2012. Accessed February 02, 2015.
36. Plummer M, Herrero R, Franceschi S, et al.,; Group IM-cCCS. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Control 2003; 14: 805-14.
37. Smoking habits [Internet]. Statistics Norway. Available from: http://www.ssb.no/en/helse/statistikker/royk. Updated Feb 03, 2015. Accessed Feb 05, 2015.
38. Bray F, Carstensen B, Moller H, et al., Incidence trends of adenocarcinoma of the cervix in 13 european countries. Cancer Epidemiol Biomarkers Prev 2005; 14: 2191-9.
39. Mitchell H, Hocking J, Saville M,. Improvement in protection against adenocarcinoma of the cervix resulting from participation in cervical screening. Cancer 2003; 99: 336-41.
40. Vaccarella S, Franceschi S, Engholm G, et al., 50 years of screening in the nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 2014; 111: 965-9.